Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)

Pesce, Gianfranco A; Klingbiel, Dirk; Ribi, Karin; Zouhair, Abderahim; von Moos, Roger; Schlaeppi, Marc; Caspar, Clemens B; Fischer, Natalie; Anchisi, Sandro; Peters, Solange; Cathomas, Richard; Bernhard, Jürg; Kotrubczik, Nina M; D'Addario, Giannicola; Pilop, Christiane; Weber, Damien C; Bodis, Stephan; Pless, Miklos; Mayer, Michael and Stupp, Roger (2012). Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). European journal of cancer, 48(3), pp. 377-84. Amsterdam: Elsevier 10.1016/j.ejca.2011.10.016

Full text not available from this repository. (Request a copy)

Patients with brain metastases (BM) rarely survive longer than 6months and are commonly excluded from clinical trials. We explored two combined modality regimens with novel agents with single agent activity and radiosensitizing properties.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bernhard, Jürg

ISSN:

0959-8049

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:20

Last Modified:

17 Mar 2015 19:26

Publisher DOI:

10.1016/j.ejca.2011.10.016

PubMed ID:

22093943

Web of Science ID:

000300729800012

URI:

https://boris.unibe.ch/id/eprint/6476 (FactScience: 211443)

Actions (login required)

Edit item Edit item
Provide Feedback